Gender Diversity In Pharma: Caught Between Desire And Reality
Charting The Executive Gender Mix Across 384 Companies
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
You may also be interested in...
Foreign firms including Merck KGaA, Boehringer Ingelheim, Takeda and Sanofi’s vaccines business are being led by women in India, a fiercely competitive, largely out-of-pocket market. There’s a lot riding on these female leaders as they seek to drive business growth and potentially change the paradigm around the gender gap in pharma at the top.
Hayden Kennedy, AbbVie’s VP of global policy and US access strategies, and one of In Vivo’s 2021 Rising Leaders, shares her approach to tackling gender diversity and discusses how a background in government has helped shape her thinking in pharma.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.